Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1

BACKGROUND: The identification of bioactive compounds from Chinese medicine plays a crucial role in the development of novel reagents against non-small lung cancer (NSCLC). METHODS: High throughput screening assay and analyses of cell growth, cell cycle, apoptosis, cDNA microarray, BrdU incorporatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Zhongya, Yao, Chao, Zhu, Xiaowen, Gong, Chenyuan, Xu, Zihang, Wang, Lixin, Li, Suyun, Zou, Chunpu, Zhu, Shiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729430/
https://www.ncbi.nlm.nih.gov/pubmed/29024939
http://dx.doi.org/10.1038/bjc.2017.319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729430/
https://www.ncbi.nlm.nih.gov/pubmed/29024939
http://dx.doi.org/10.1038/bjc.2017.319

Ejemplares similares